Bio & Pharma
Prestige Biopharma participates in US gov’t Cancer Moonshot
It takes part in President Biden’s project to conquer cancer, with a pancreatic cancer drug candidate and diagnostic kit
By Jul 18, 2023 (Gmt+09:00)
1
Min read
Most Read
LG Chem to sell water filter business to Glenwood PE for $692 million


Kyobo Life poised to buy Japan’s SBI Group-owned savings bank


KT&G eyes overseas M&A after rejecting activist fund's offer


StockX in merger talks with Naver’s online reseller Kream


Mirae Asset to be named Korea Post’s core real estate fund operator



Prestige Biopharma, a Singapore-based biopharmaceutical company with operations in South Korea and the US, announced on Tuesday that it will participate in the US government's cancer eradication project "Cancer Moonshot."
According to company sources, CancerX, a public-private collaboration established to drive the Cancer Moonshot, has selected Prestige Biopharma as a member, recognizing that its pancreatic cancer treatment strategy aligns with the project's goals.
The company explained that since CancerX publicly disclosed around 90 founding member companies last month, it has been actively enlisting additional companies in the field of cancer therapeutics.
Prestige Biopharma possesses drug candidates such as PBP1510 (ulenistamab), which neutralizes the gene PAUF (pancreatic adenocarcinoma up-regulated factor) excessively expressed in pancreatic cancer patients. Through this participation, the company plans to conduct various research related to pancreatic cancer diagnosis, treatment, and prevention utilizing PAUF concentrations.
The Cancer Moonshot was initially mentioned during the tenure of former US President Barack Obama, with the aim of national support for cancer prevention, early detection and the development of therapies. It is currently being pursued by President Joe Biden.
Write to In-hyuk Park at hyuk@hankyung.com
More to Read
-
Bio & PharmaPrestige Bio's pancreatic cancer treatment gets US FDA fast-track designation
Mar 16, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaPrestige Bio's Herceptin biosimilar proves equivalence in clinical trials
Feb 08, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaPrestige Biopharma submits clinical trial plan in Australia
Feb 03, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaPrestige Biopharma attains patent for solid cancer treatment antibody
Jan 12, 2023 (Gmt+09:00)
1 Min read
Comment 0
LOG IN